<DOC>
	<DOCNO>NCT02969525</DOCNO>
	<brief_summary>This study evaluate dose response base efficacy , safety tolerability bimekizumab subject active psoriatic arthritis .</brief_summary>
	<brief_title>A Multicenter Study Evaluate Dose Response Based Efficacy , Safety Tolerability Bimekizumab Subjects With Active Psoriatic Arthritis Which Type Inflammatory Arthritis .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<criteria>Subject document diagnosis adultonset PsA classify Classification Criteria Psoriatic Arthritis ( CASPAR ) criterion symptom least 6 month prior Screening , active psoriatic arthritis ( PsA ) Baseline/Day 1 , must Baseline tender joint count ( TJC ) &gt; =3 78 swell joint count ( SJC ) &gt; =3 76 Subject must rheumatoid factor anticyclic citrullinated peptide ( CCP ) antibodies negative Subject must active psoriatic lesion ( ) and/or documented history psoriasis Subjects regularly take nonsteroidal antiinflammatory drug ( NSAIDs ) /COX2 inhibitor part PsA therapy require stable dose/dose regimen least 14 day Baseline Subjects take corticosteroid must average daily dose &lt; =10mg/day prednisone equivalent least 14 day Baseline remain stable dose Week 16 visit Subjects take methotrexate ( MTX ) ( &lt; =25mg /week ) allow continue medication start least 12 week prior Baseline , stable dose least 8 week randomization Subjects take leflunomide ( LEF ; &lt; =20mg/day average 20mg/day dosed daily ) allow continue medication start least 3 month prior Baseline , stable dose least 8 week randomization . Dose dose schedule remain stable Week 16 Subjects may tumor necrosis factor ( TNF ) inhibitor na√Øve may receive 1 prior TNF inhibitor . Subjects TNF inhibitor previously must : 1. experience inadequate response previous treatment give least 3 month 2. intolerant administration ( eg , sideeffect/adverse event ( AE ) lead discontinuation ) 3. lost access TNF inhibitor reason Subjects current sign symptom may indicate active infection ( exception common cold ) infection require systemic antibiotic within 2 week Baseline/Day 1 Subjects history chronic recurrent infection , serious lifethreatening infection within 6 month prior Baseline Visit Subjects concurrent acute chronic viral hepatitis B C human immunodeficiency virus ( HIV ) infection Subjects know history current clinically active infection Histoplasma , Coccidioides , Paracoccidioides , Pneumocystis , Blastomyces , Aspergillus current active Candidiasis Subjects receive live ( include attenuate ) vaccination within 8 week prior Baseline Subjects know tuberculosis ( TB ) infection , high risk acquire TB infection , latent TB infection ( LTBI ) , current history nontuberculous mycobacteria ( NTMB ) infection Subjects diagnosis inflammatory condition psoriasis psoriatic arthritis Subjects concurrent malignancy history malignancy past 5 year exclude , follow exception may include : 1 . &lt; = 3 excise ablate basal cell carcinoma skin 2 . One squamous cell carcinoma skin ( stage T1 maximum ) successfully excise , ablate ( treatment , ie , chemotherapy , apply ) , sign recurrence metastases 2 year prior Screening 3 . Actinic keratosis ( e ) 4 . Squamous cell carcinomainsitu skin successfully excise , ablate , 6 month prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>PsA</keyword>
	<keyword>Bimekizumab</keyword>
</DOC>